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Letter to the EditorRisk factors for Haemophilus influen-
zae and pneumococcal respiratory
tract colonization in CVIDTo the Editor:
Disease-specific studies focused on infection risk in common
variable immune deficiencies (CVIDs) are needed to define
strategies for controlling respiratory infections predominantly
due to bacteria such as Streptococcus pneumoniae andHaemophi-
lus influenzae.1 Little information is available on the rate of
airway bacterial carriage and its consequence in hypogammaglo-
bulinemias. Despite IgG replacement, recurrent respiratory infec-
tions are common in CVID, possibly leading to chronic lung
damage2 and poor quality of life.3 Thus, patients are often pre-
scribed antibiotics and/or long-term antimicrobial prophylactic
regimens. Several regimens are used including rotation or period-
ically changing antibiotics.4 However, antibiotics influence anti-
microbial resistance among airway microbiota. In a recent
meta-analysis on patients with chronic lung diseases, 30% of
S pneumoniae showed resistance to macrolides.5
In this observational longitudinal study, we investigated the
rate of nasopharyngeal and oropharyngeal mucosal carriage of S
pneumoniae and H influenzae identified by cultural methods and
real-time PCR (RT-PCR), the antimicrobial susceptibility pat-
terns, and the antibiotic usage in adult patients with CVID
(http://esid.org/Working-Parties/Registry/Diagnosis-criteria). In
addition, we verified whether colonization would be associated
with risk for respiratory infections.
Exclusion criteria for swabs collection included acute respira-
tory infections and antibiotic treatment in the month preceding
the swabs collection except for antibiotic prophylaxis. Rate of
respiratory infections, clinical data, and days of antibiotic usage
in the 6 months before swabs collection were recorded. After
swabs collection, respiratory infections were recorded for an
additional 6 months. Sample collection and identification of S
pneumoniae and H influenzae were performed according to the
World Health Organization standard procedures by cultural and
molecular methods on nasopharyngeal and oropharyngeal swabs
collected on the same day. For both bacterial species, minimum
inhibitory concentrations of antimicrobial agents were deter-
mined. The interpretative criteria were based on European Com-
mittee on Antimicrobial Susceptibility Testing (EUCAST)
breakpoints (http://www.eucast.org/clinical breakpoints/) (see
the Methods section in this article’s Online Repository at www.
jacionline.org).
The 12-month study included 93 patients with CVID (mean
age, 49.4 6 14.4 years; range, 18-77) with a 1:1 male to female
ratio. Participants were on IgG replacement at a monthly cumu-
lative dose of 400mg/kg.Mean IgG trough levels at the study time
were 688.8 6 156.0 mg/dL. Nineteen patients were exposed to
children younger than 6 years at home or through work. Thirty-
four (41%) patients had bronchiectasis and 9 (9.6%) were on
chronic antibiotic prophylaxis. 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The carriage prevalence by culture was 10.8% and 26.9% for S
pneumoniae and H influenzae, respectively, regardless of the
isolation site (see Table E1 in this article’s Online Repository at
www.jacionline.org). Four percent of CVID were cocolonized
by both S pneumoniae and H influenzae. In line with other pneu-
mococcal carriage studies, after the long-term use of glycoconju-
gate vaccines, we found only 20% of the 13 pneumococcal
isolates belonging to vaccine serotypes6: 10A and 19A (2 isolates
each), 6A, 12F, 23A, 35F, and 37 (1 isolate each); 4 isolates were
nontypeable. All 36 H influenzae isolates were nontypeable, con-
firming the absolute prevalence of this serotype, especially among
respiratory tract isolates, in the present Hib vaccination era (see
Table E2 in this article’s Online Repository at www.jacionline.
org).
Compared with culture, RT-PCR allowed identifying a higher
carriage rate of Spneumoniae and/or H influenzae (10.8% vs
52.7%, P < .0001 and 26.9% vs 39.8%, P 5 .043, respectively).
In the RT-PCR assay, the cycle threshold value was significantly
lower in samples found positive by culture compared with those
positive by RT-PCR, suggesting that the former samples had a
higher S pneumoniae and/or H influenzae bacterial load. By RT-
PCR the percentage of CVID cocolonized carriers significantly
increased (4% vs 24%; P 5 .0001). H influenzae/S pneumoniae
carriers identified by only RT-PCR had a milder immunological
defect than culture-positive patients (IgA, 15.8 6 3.2 vs
2.7 6 0.9 mg/dL, P 5 .0001; IgM, 22.2 6 4.4 vs 9.9 6 4.1,
P 5 .030).
Risk factors related to colonization were initially identified by
binary logistic regression. Low IgM and low IgA serum levels
were found to be risk factors for S pneumoniae and H influenzae
colonization. Colonization by culture was associated with IgM
serum levels of less than 5 mg/dL (odds ratio [OR], 3.7; 95%
CI, 0.86-15.99; P 5 .05; OR, 2.5; 95% CI, 0.95-6.45; P 5 .05,
respectively) and with IgA serum levels of less than 7 mg/dL
(OR, 5.7; 95% CI, 0.69-47.17; P 5 .05; OR, 8.9; 95% CI,
1.92-40.84; P 5 .001, respectively). Of note, patients cocolon-
ized had particularly low IgA and IgM serum levels
(1.3 6 0.7 mg/dL and 1.7 6 1.2 mg/dL, respectively). This
confirmed data on patients with hyper-IgM syndrome and
healthy subjects where IgM antibodies have a distinct anti–H in-
fluenzae activity in the prevention of respiratory tract bacterial
colonization.7-9
Other potential risk factors such as age, previous respiratory
infections, bronchiectasis, chronic lung diseases, IgG trough level
of less than 600 mg/dL, and defects in other immunological
parameters were not associated with colonization. Antibiotic use
and long-term prophylaxis in the previous 6 months were not
associated with H influenzae and S pneumoniae colonization.
However, participants exposed to young children were more
likely to be colonized by H influenzae (OR, 5.9; 95% CI, 2.00-
13.36; P5 .001), but not by S pneumoniae. Multivariate analysis
confirmed that IgA serum levels of less than 7 mg/dL (OR, 5.4;
95% CI, 1.08-26.70; P 5 .040) and the presence of children
younger than 6 years in the house/workplace (OR, 4.5; 95% CI,
1.37-14.50; P 5 .013) had a direct effect on H influenzae coloni-
zation (Table I).
Carriers identified by culture, but not by RT-PCR, had a higher
risk of upper respiratory tract infection but not lower respiratory1
TABLE I. Risk factors for S pneumoniae and H influenzae colonization as detected by culture
n (%)
Univariate analysis Multivariate analysis
S pneumoniae H influenzae H influenzae
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Sex (female) 47 (51.1) 0.95 0.25-3.54 NS 0.70 0.27-1.70 NS — — —
Age < 35 y 12 (12.9) 3.52 0.77-16.10 NS 1.43 0.39-5.23 NS — — —
IgM < 5 mg/dL 34 (38.2) 3.71 0.86-15.99 .05 2.48 0.95-6.44 .05 1.63 0.55-4.79 NS
IgA < 7 mg/dL 58 (65.2) 5.69 0.69-47.17 .05 8.86 1.92-40.84 .001 5.36 1.08-26.7 .040
IgG trough level <600 mg/dL 8 (8.6) 0.60 0.16-2.35 NS 0.71 0.26-1.82 NS — — —
Exposition to children 19 (20.4) 0.42 0.05-3.38 NS 5.89 2.00-17.36 .001 4.45 1.37-14.50 .013
URTI in the previous 6 mo 21 (25.0) 1.74 0.45-6.73 NS 0.93 0.34-2.58 NS — — —
LRTI in the previous 6 mo 32 (38.5) 1.86 0.50-6.96 NS 1.54 0.60-3.92 NS — — —
CLD 49 (53.3) 0.55 0.14-2.09 NS 0.93 0.37-2.34 NS — — —
Bronchiectasis 34 (36.5) 1.08 0.27-4.37 NS 0.82 0.31-2.18 NS — — —
Use of antibiotics in the previous 6 mo 47 (50.5) 0.98 0.26-3.63 NS 0.87 0.35-2.18 NS — — —
Amoxicillin/Clavulanic acid 21 (24.4) 1.20 0.22-6.57 NS 0.97 0.30-3.17 NS — — —
Macrolides 13 (15.1) 1.97 0.35-11.15 NS 1.21 0.33-4.50 NS — — —
Antibiotic prophylaxis 9 (9.7) 1.04 0.12-9.31 NS 0.75 0.15-3.91 NS — — —
CD31CD41 <400 cell/mm3 22 (31.4) 3.41 0.69-16.76 NS 0.81 0.25-2.66 NS — — —
CD191 <8% 36 (51.4) 1.67 0.37-7.59 NS 0.69 0.23-2.01 NS — — —
CD271IGD2IgM2 <3% 30 (56.6) 1.03 0.21-5.11 NS 2.08 0.60-7.19 NS — — —
CLD, Chronic lung disease; LRTI, lower respiratory tract infection; NS, not significant; URTI, upper respiratory tract infection.
FIG 1. URTIs over the 6 months after colonization status assessment.URTI,
Upper respiratory tract infection. Red lines: Patients with CVID colonized by
S pneumoniae (Sp) and/or H influenzae (Hi); Green lines: not colonized.
J ALLERGY CLIN IMMUNOL
nnn 2018
2 LETTER TO THE EDITORtract infection within 3 months of swabs collection (hazard ratio,
3.0; 95% CI, 1.0-9.20; Log-rank test P 5 .05), with the highest
levels of significance recorded within 60 days (hazard ratio, 4.1;
95% CI, 1.70-10.0; Log-rank test P 5 .002; Fig 1). Thus, the
lack of a clinical correlation with RT-PCR data did not allow to
suggest to routinely adopt RT-PCR in the colonization assessment
of patients with primary antibody deficiencies.
The actual impossibility to replace IgA and IgM at the mucosal
level implied the need to consider additional therapeutic in-
terventions in primary antibody deficiencies. such as the use of
antibiotic treatment or prophylaxis. However, a major concern
related to the use of antibiotic therapy or prophylaxis is that it
exerts selective pressure on airway microbiota, facilitating the
emergence of antibiotic resistance. Our study added information
on rates of antibiotic resistance in S pneumoniae andH influenzae
isolates in CVID. As shown in Table E2, only 3 of 13 pneumo-
coccal isolates were susceptible to all antibiotics tested (peni-
cillin, ceftriaxone, erythromycin, clindamycin, levofloxacin). In
particular, 9 of 13 pneumococcal isolates were nonsusceptible
to penicillin. However, only 1 isolate was fully resistant, whereasthe others showed low-level penicillin resistance, which is consid-
ered potentially overcome by high-dose penicillin in case of res-
piratory infections.
Differently, 19 of 36 H influenzae isolates were susceptible to
all antibiotics tested. Ampicillin and azithromycin resistance
was the most frequently detected: 9 of 36 isolates were resistant
to ampicillin and 10 of 36 were resistant to azithromycin.
Although the EUCAST breakpoint tables (Version 8, 2018) no
longer report clinical breakpoints of macrolide for H influenzae
in respiratory infections, it indicates the epidemiological cutoffs
to detect isolates with acquired macrolide resistance. In the
6 months preceding the swabs collection, beta-lactams were the
most frequently administered antibiotic (22 patients), followed
by macrolides (14 patients). Carriers of susceptible strains were
never treated by beta-lactams and/or macrolides, whereas carriers
of strains nonsusceptible to beta-lactams and macrolides were
treated for a mean of 14.4 6 6.6 days (P 5 .05). In conclusion,
in CVID very low IgA serum level is a risk factor for carriage
and colonization acts as a bacteria reservoir and as a risk factor
for respiratory complications.
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METHODS
Nasopharyngeal and oropharyngeal swabs were collected once for each
patient and transferred to the laboratory within 4 hours of collection. Aliquots of
STGG medium were streaked on 5% sheep blood Columbia agar plates
supplemented with 5 mg/mL gentamycin to isolate S pneumoniae and on choc-
olate blood agar containing Vitox, bacitracin, vancomycin, and amphotericin B
(Haemophilus Selective Agar, Oxoid Ltd, Basingstoke, Hampshire, UK) to
selectively culture H influenzae. Colonies resembling S pneumoniae or H influ-
enzae were further identified by standard microbiological tests. S pneumoniae
isolates were serotyped by the Quellung reaction using commercially available
antisera (Statens Serum Institut, Copenhagen,Denmark). The capsular genotype
of H influenzae isolates was determined by PCR, as previously reported.E1 For
molecular detection of S pneumoniae and H influenzae in nasopharyngeal and
oropharyngeal specimens, genomic DNAwas extracted from STGG broths us-
ing QIAmp DNA Mini kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. S pneumoniae was detected by RT-PCR targeting the
lytA gene and using primers and probes previously described.E2 For H influen-
zae, RT-PCR was carried out targeting the hpd gene with primers hpdF822 and
hpdR952 and following conditions previously reported.E3
Antimicrobial susceptibility testing
For both bacterial species, minimum inhibitory concentrations (MICs) of
antimicrobial agents were determined by E-test (Etest, bioMerieux, Durham,
NC).The interpretative criteriawere basedonEUCASTbreakpoints (http://www.
eucast.org/clinical breakpoints/). The antimicrobial agents tested inMICdetermi-
nation were penicillin, ceftriaxone, erythromycin, clindamycin, and levofloxacin
for Spneumoniae isolates and ampicillin, amoxicillin-clavulanic acid, azithromy-
cin, cefotaxime, ciprofloxacin, and meropenem for H influenzae isolates.
Analyses
Patients’ demographic characteristics and clinical characteristics were
expressed by mean 6 SD or by frequencies, where appropriate. The
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outcome measures in this analysis were colonization by S pneumoniae and
colonization by H influenzae identified by traditional culture and by RT-
PCR. Clinical and immunological characteristics were investigated to
reveal the relationships between the variable and each outcome measure.
Comparison of continuous variables was performed by the unpaired t
test. We calculated differences in frequencies between groups using Fisher
exact test. To determine which variables to consider for building the multi-
variate logistic regression model for H influenzae and/or S pneumoniae, a
binary logistic regression was run. Variables with a P value of less than .25
were considered for the multivariate logistic regression model. The back-
wards stepwise selection method was used to build the multivariate model.
We computed the pooled ORs for end points with 95% CI. Cutoff points
for age, CD191CD271IgD2IgM2 frequency, IgM serum levels, and
IgA serum levels were based on the highest sensitivity value plus the spec-
ificity identified by the receiver-operating characteristics curve method
curve between S pneumoniae and/or H influenzae colonized and not colo-
nized patients. Infections-survival rates were estimated by using the
Kaplan-Meier method. The statistical significance was set at the conven-
tional level of P < .05. All statistical analyses were performed using the
statistical package STATA 11 (StataCorp LP, College Station, Tex).
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TABLE E1. S pneumoniae and H influenzae colonization by cul-
ture and RT-PCR in CVID
Species/isolation site
CVID (n 5 93), n (%)
Culture1 RT-PCR1
S pneumoniae
Nasopharynx and/or oropharynx 10 (10.8) 49 (52.7)
Nasopharynx 8 (8.6) 32 (34.4)
Oropharynx 6 (6.5) 35 (37.6)
H influenzae
Nasopharynx and/or oropharynx 25 (26.9) 37 (39.8)
Nasopharynx 22 (23.7) 30 (32.3)
Oropharynx 14 (15.1) 27 (29.0)
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TABLE E2. Serotype and antibiotic susceptibility of S pneumoniae and H influenzae isolates from nasopharynx and oropharynx in
patients with CVID
Spneumoniae
serotype Site n
PG
R/I
TX
I
EM
R
CL
R
LV
R
H influenzae
serotype Site n
AM
R
XL
R
CT
R
AZ
R
CI
R
MP
R
6A* NP 1 Yes Yes Yes Yes No NTHi NP 6 No No No Yes No No
10A NP 1 No No No No No NTHi NP 4 Yes No No No No No
12F NP 1 No No No No No NTHi NP 1 Yes No No Yes No No
19A NP 1 Yes No Yes Yes No NTHi NP 1 Yes Yes No No Yes No
23A NP 1 No No Yes Yes No NTHi NP 10 No No No No No No
35F NP 1 Yes No No No No NTHi OP 2 Yes No No No No No
NT NP 1 Yes No Yes Yes Yes NTHi OP 2 No No No Yes No No
NT NP 1 Yes No Yes No No NTHi OP 1 Yes No No Yes No No
10A OP 1 No No No No No NTHi NP 9 No No No No No No
19A OP 1 Yes No Yes Yes No
37 OP 1 Yes Yes Yes No No
NT OP 1 Yes Yes Yes Yes Yes
NT OP 1 Yes No Yes No No
Total 15 10 3 10 7 2 36 9 1 0 10 1 0
AM, Ampicillin; AZ, azithromycin; CI, ciprofloxacin; CL, clindamycin; CT, cefotaxime; EM, erythromycin; I, intermediate; LV, levofloxacin; MP, meropenem; NP, nasopharynx;
NT, nontypeable; NTHi, nontypeable H inlfuenzae; OP, oropharynx; PG, penicillin; R, resistant; TX, ceftriaxone; XL, amoxicillin-clavulanic acid.
*S pneumoniae isolate fully resistant to penicillin.
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